
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is supported by a growing commercial base, with 3Q:26 product sales of $1.27 billion and raised 2026 revenue guidance to 15-25% growth, while its $8 billion cash balance and $3.19 billion in long-term debt suggest ample financial flexibility. Its outlook is further strengthened by the Phase III INTerpath-001 results, where intismeran plus KEYTRUDA improved recurrence-free survival by 42% and distant metastasis-free survival by 38%, supporting a 2027 adjuvant melanoma approval and potential expansion into other cancers. Beyond oncology, Moderna’s 25 clinical mRNA candidates across infectious disease, cardiovascular disease, and rare genetic disease, plus approved COVID and flu vaccines, provide multiple shots of revenue diversification and long-term growth.
Bears say
Moderna is a commercial-stage biotech whose investment case is weakened by heavy dependence on mRNA programs that could fail in the clinic or never secure approval, despite having 25 candidates in clinical studies as of March 2026 across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company’s sales may also fall short of forecasts while spending runs above budget, pressuring future profitability and making its broad pipeline less valuable if execution slips. In particular, the decision not to conduct a 3rd season of the Phase III NOVA-301 trial and instead seek FDA guidance on mRNA-1403 forced a $1.01 billion value reduction, underscoring meaningful development and regulatory uncertainty.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Moderna (MRNA) Forecast
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares